Antares Pharma Inc (NASDAQ:ATRS)’s share price was down 7.5% during mid-day trading on Tuesday . The stock traded as low as $2.21 and last traded at $2.21. Approximately 1,853,754 shares were traded during mid-day trading, an increase of 41% from the average daily volume of 1,314,857 shares. The stock had previously closed at $2.39.
A number of equities research analysts have recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $3.50 target price on shares of Antares Pharma in a report on Wednesday, November 8th. Piper Jaffray Companies set a $3.00 target price on shares of Antares Pharma and gave the company a “buy” rating in a report on Monday, October 23rd. Finally, BidaskClub raised shares of Antares Pharma from a “hold” rating to a “buy” rating in a report on Friday, December 22nd. One research analyst has rated the stock with a sell rating, four have issued a buy rating and two have issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $3.94.
The company has a current ratio of 3.34, a quick ratio of 2.89 and a debt-to-equity ratio of 0.69. The company has a market capitalization of $345.66, a price-to-earnings ratio of -20.09 and a beta of 0.30.
Several large investors have recently made changes to their positions in ATRS. Capital Advantage Inc. purchased a new stake in shares of Antares Pharma in the third quarter valued at about $110,000. Virtu Financial LLC purchased a new stake in shares of Antares Pharma in the fourth quarter valued at about $117,000. Alliancebernstein L.P. purchased a new stake in shares of Antares Pharma in the second quarter valued at about $119,000. First Eagle Investment Management LLC raised its holdings in shares of Antares Pharma by 150.0% in the third quarter. First Eagle Investment Management LLC now owns 50,000 shares of the specialty pharmaceutical company’s stock valued at $162,000 after buying an additional 30,000 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership purchased a new stake in shares of Antares Pharma in the second quarter valued at about $174,000. 34.20% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: “Antares Pharma (ATRS) Trading Down 7.5%” was originally reported by Stock Observer and is owned by of Stock Observer. If you are viewing this news story on another site, it was copied illegally and republished in violation of international trademark & copyright laws. The legal version of this news story can be read at https://www.thestockobserver.com/2018/02/20/antares-pharma-atrs-trading-down-7-5.html.
Antares Pharma Company Profile
Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.
Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.